Drug Trial Radar · NCT07871110
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Dec 31, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if tinengotinib combined with darolutamide or enzalutamide works to treat participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen receptor pathway inhibitors (ARPIs). It will also learn about the safety of the combination therapy. The main questions it aims to answer are: 1. If participants with mCRPC can benefit from the combination therapy of tinengotinib plus one ARPI? 2. What medical problems do participants have when taking the combination therapy? Participants will take tinengotinib with darolutamide or enzalutamide to find the optimal dose and regimen of tinengotinib for the combination therapy in stage A. In stage B, participants will take preferred combination regimen of tinengotinib plus darolutamide/enzalutamide identified in stage A. In stage C, researchers will compare selected combination therapy versus standard treatment and/or monotherapy to see if the combination therapy works better.
Conditions
- Prostate Cancer (CRPC)
Interventions
tinengotinib 10 mg QD plus darolutamideDrug
Participants will receive tinengotinib 10 mg once daily with darolutamide in 21-day cycles per protocol defined schedule.
tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamideDrug
Participants will receive tinengotinib 10 mg once daily (2-week on / 1-week off) with darolutamide in 21-day cycles per protocol defined schedule.
tinengotinib 10 mg QD plus enzalutamideDrug
Participants will receive tinengotinib 10 mg once daily with enzalutamide in 21-day cycles per protocol defined schedule.
preferred combination regimen of tinengotinib plus one ARPIDrug
Participants will receive preferred combination regimen of tinengotinib at optimized dose plus one ARPI in 21-day cycles per protocol defined schedule.
selected combination regimen of tinengotinib plus one ARPIDrug
Participants will receive selected combination regimen of tinengotinib at optimized dose plus one ARPI in 21-day cycles per protocol defined schedule.
Darolutamide 600 mg twice dailyDrug
Participants will receive darolutamide 600 mg twice daily in 21-day cycles per protocol defined schedule.
Enzalutamide 160mg daily (oral)Drug
Participants will receive enzalutamide 160mg daily (oral) in 21-day cycles per protocol defined schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage A: safety evaluation parametersTime frame: From signing of the informed consent until 28 days after the last dose or the end of the study (whichever occurs first), an average of 1 year.
- Stage B: 6-month PFS rate (6mo-PFS)Time frame: From first study drug administration to the end of treatment, an average of 1 year.
- Stage C: Radiographic progression-free survival (rPFS)Time frame: From first study drug administration to the end of treatment, an average of 1 year.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, China · Not yet recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China · Not yet recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China · Recruiting
Nantong Cancer Hospital
Nantong, Jiangsu, China · Not yet recruiting
Shandong Cancer Hospital and Institute, Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
The First Hospital of Jiaxing
Jiaxing, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.